drugset / Trial / NCT04164212

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

NCT04164212

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)

Timeline

Start
2020-09-01
Primary completion
2026-01-22
Completion
2026-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine 0.2 ml Intranasal

Indications